Also known as: J&J
Johnson & Johnson is a global healthcare company focused on innovative medicine and medtech. The company says it has been helping people stay well at every age and stage of life since 1886 and operates across the full spectrum of healthcare solutions.
Johnson & Johnson faces new talc verdicts in Minnesota and Pennsylvania totaling over $10 million, with 67,000+ lawsuits pending. Meanwhile, the FDA approved a new monthly dosing for RYBREVANT FASPRO, and the company launched its Shockwave C2 Aero coronary catheter globally.
Trump secured agreements with 16 pharmaceutical companies tied to TrumpRx.gov, including most-favoured-nation pricing and direct-to-patient discounts. Several companies disclosed price cuts for obesity, diabetes, insulin and other medicines.
The global schizophrenia drugs market is projected to grow from USD 9.1 billion in 2026 to USD 15.8 billion by 2036 at a 5.8% CAGR. Long-acting injectables and second-generation antipsychotics lead the market.
Johnson & Johnson said Tremfya met the primary endpoint in the Phase 3 FUZION study in active perianal fistulizing Crohn’s disease. At Week 24, both Tremfya dosing regimens showed statistically significant combined fistula remission versus placebo.
A Pennsylvania jury ordered Johnson & Johnson to pay $250,000 to the family of Gayle Emerson in a talc baby powder ovarian cancer case. The verdict comes amid more than 90,000 talc lawsuits and ongoing fights over expert testimony.
Healthcare stocks were described as a defensive sector facing 2026 reimbursement headwinds, while capex rankings showed HCA Healthcare, Johnson & Johnson and Merck at the top. The sources also highlighted how capex differs across providers, device makers and drug developers.
Johnson & Johnson raised its full-year forecast after stronger-than-expected quarterly results driven by cancer, immunology and neuroscience drugs. Sales were $24.56 billion and adjusted earnings were $2.46 per share, with Innovative Medicines sales rising 10.0% to $15.76 billion.
Johnson & Johnson said revenue could reach about $100.5 billion at the midpoint in 2026 after 2024 net sales rose 6% to $94.2 billion. The company faces talc litigation, Stelara patent losses and U.S. drug price negotiations.
Johnson & Johnson shares hit a 52-week high after the company reported 2025 revenue of $94.19 billion and forecast 2026 revenue above $100 billion. The company also filed a shelf registration and said Innovative Medicine growth offset pressure from Stelara.
The FDA has approved icotrokinra, the first oral IL-23 therapy for moderate-to-severe plaque psoriasis. Meanwhile, real-world research shows IL-23 inhibitors produce site-specific responses in high-impact areas like scalp and nails, and combination therapy with ixekizumab and tirzepatide shows superior results for psoriasis patients with obesity.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07551856 |
Manual Arthroplasty Versus VELYS Robotic-Assisted Solution Functional Alignment Arthroplasty for Knee Osteoarthritis |
NOT_YET_RECRUITING | NA |
| NCT07534462 |
Echocardiographic Assessment of the Effect of Impella on Biventricular Function |
NOT_YET_RECRUITING | |
| NCT07532473 |
REal World MAIA UK OutcomEs |
NOT_YET_RECRUITING | |
| NCT07507409 |
Innovative Sternal Closure Techniques: Evaluating STRATAFIX™ and DERMABOND™ for Reduced Complications in CABG Patients |
NOT_YET_RECRUITING | PHASE4 |
| NCT07361055 |
The Best Workflow for Paroxysmal Supraventricular Tachycardia Ablation With Zero-fluoroscopy |
ENROLLING_BY_INVITATION | NA |
| NCT07354217 |
Workflow Optimization During Pulse Field Ablation for Atrial Fibrillation |
NOT_YET_RECRUITING | PHASE4 |
| NCT07254455 |
CASTLE-HFpEF (Catheter Ablation for Atrial Fibrillation Patients With Heart Failure With Mildly Reduced and Preserved Ejection Fraction) |
NOT_YET_RECRUITING | NA |
| NCT07225101 |
Evaluation of the Efficacy of STRATAFIX for Neurosurgical Cranial and Spine Procedures |
RECRUITING | PHASE4 |
| NCT07105059 |
A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma |
RECRUITING | PHASE1 |
| NCT07075510 |
Subcutaneous Daratumumab Administration in the Thigh Vs Abdomen in Plasma Cell Disorders |
RECRUITING | PHASE1/PHASE2 |
